[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20010604L - Hepatitt C inhibitorpeptider - Google Patents

Hepatitt C inhibitorpeptider

Info

Publication number
NO20010604L
NO20010604L NO20010604A NO20010604A NO20010604L NO 20010604 L NO20010604 L NO 20010604L NO 20010604 A NO20010604 A NO 20010604A NO 20010604 A NO20010604 A NO 20010604A NO 20010604 L NO20010604 L NO 20010604L
Authority
NO
Norway
Prior art keywords
hepatitis
inhibitor peptides
peptides
inhibitor
Prior art date
Application number
NO20010604A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010604D0 (no
Inventor
Montse Llinas-Brunet
Murray D Bailey
Dale Cameron
Elise Ghiro
Nathalie Goudreau
Marc-Andre Poupart
Jean Rancourt
Youla S Tsantrizos
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Publication of NO20010604D0 publication Critical patent/NO20010604D0/no
Publication of NO20010604L publication Critical patent/NO20010604L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20010604A 1998-08-10 2001-02-05 Hepatitt C inhibitorpeptider NO20010604L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9594598P 1998-08-10 1998-08-10
PCT/CA1999/000737 WO2000009558A1 (en) 1998-08-10 1999-08-09 Hepatitis c inhibitor peptides

Publications (2)

Publication Number Publication Date
NO20010604D0 NO20010604D0 (no) 2001-02-05
NO20010604L true NO20010604L (no) 2001-02-05

Family

ID=22254308

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010604A NO20010604L (no) 1998-08-10 2001-02-05 Hepatitt C inhibitorpeptider

Country Status (33)

Country Link
EP (1) EP1105422B1 (cs)
JP (1) JP4435982B2 (cs)
KR (1) KR100629791B1 (cs)
CN (1) CN1166690C (cs)
AR (1) AR022061A1 (cs)
AT (1) ATE317854T1 (cs)
AU (1) AU764655B2 (cs)
BG (1) BG64956B1 (cs)
BR (1) BR9912943A (cs)
CA (1) CA2336597C (cs)
CO (1) CO5180537A1 (cs)
CZ (1) CZ301405B6 (cs)
DE (1) DE69929887T2 (cs)
DK (1) DK1105422T3 (cs)
EA (1) EA004765B1 (cs)
EE (1) EE200100080A (cs)
ES (1) ES2257066T3 (cs)
HK (1) HK1039947B (cs)
HR (1) HRP20010101A2 (cs)
HU (1) HUP0104548A3 (cs)
ID (1) ID27784A (cs)
IL (2) IL141011A0 (cs)
MY (1) MY125014A (cs)
NO (1) NO20010604L (cs)
NZ (1) NZ510395A (cs)
PL (1) PL199419B1 (cs)
RS (1) RS49819B (cs)
SK (1) SK286846B6 (cs)
TR (1) TR200100438T2 (cs)
TW (1) TW577895B (cs)
UA (1) UA73480C2 (cs)
WO (1) WO2000009558A1 (cs)
ZA (1) ZA200100972B (cs)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
IL151934A0 (en) 2000-04-05 2003-04-10 Schering Corp Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
KR20020097220A (ko) 2000-04-19 2002-12-31 쉐링 코포레이션 알킬 및 아릴 알라닌 ｐ2 잔기를 포함하는 ｃ형 간염바이러스의 매크로사이클릭 ｎｓ3-세린 프로테아제 억제제
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
HU229997B1 (en) * 2000-07-21 2015-04-28 Dendreon Corp San Diego Peptides as ns3-serine protease inhibitors of hepatitis c virus
JP4452441B2 (ja) 2000-07-21 2010-04-21 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CN1301994C (zh) 2000-12-12 2007-02-28 先灵公司 作为c型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的二芳基肽
CA2449504A1 (en) * 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
CA2462163A1 (en) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
EP1467989B1 (en) 2002-01-23 2009-09-23 Schering Corporation Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2003087092A2 (en) 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ES2354282T3 (es) 2003-03-05 2011-03-11 Boehringer Ingelheim International Gmbh Análogos peptídicos inhibidores de la hepatitis c.
EP1601685A1 (en) 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
KR100971347B1 (ko) * 2003-03-08 2010-07-20 주식회사유한양행 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
US7148347B2 (en) 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CN103203010A (zh) 2003-05-21 2013-07-17 贝林格尔.英格海姆国际有限公司 包含丙型肝炎抑制剂化合物的药物组合物
MXPA06002250A (es) 2003-08-26 2006-05-17 Schering Corp Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c.
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
UY28525A1 (es) 2003-09-22 2005-04-29 Boehringer Ingelheim Int Péptidos macrociclicos activos contra en virus de la hepatitis c
MXPA06003455A (es) 2003-09-26 2006-05-31 Schering Corp Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c.
AP2287A (en) 2003-10-14 2011-10-31 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
ES2389201T3 (es) 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1689770A1 (en) * 2003-11-20 2006-08-16 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2005056182A1 (en) 2003-12-08 2005-06-23 Boehringer Ingelheim International, Gmbh Removal of ruthenium by-product by supercritical fluid processing
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
UA84050C2 (en) 2004-01-30 2008-09-10 Медивир Аб Hcv ns-3-serine protease inhibitors
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
SI1719773T1 (sl) 2004-02-24 2009-08-31 Japan Tobacco Inc Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2005087730A1 (en) * 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
DE602005023224D1 (de) 2004-02-27 2010-10-07 Schering Corp Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
WO2005085275A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
CA2557247A1 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
JP4714732B2 (ja) 2004-02-27 2011-06-29 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての硫黄化合物
EP1730166B1 (en) 2004-03-15 2010-03-03 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
EA012389B1 (ru) * 2004-03-30 2009-10-30 Интермун, Инк. Макроциклические соединения в качестве ингибиторов вирусной репликации
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
JP5156374B2 (ja) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7550559B2 (en) 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2006030892A1 (ja) * 2004-09-17 2006-03-23 Nippon Shinyaku Co., Ltd. 複素環化合物の製造方法
WO2006039488A2 (en) 2004-10-01 2006-04-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease inhibition
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006096652A2 (en) 2005-03-08 2006-09-14 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AP2007004245A0 (en) 2005-05-13 2007-12-31 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA019888B1 (ru) 2005-07-25 2014-07-30 Интермьюн, Инк. Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP1915378A4 (en) 2005-08-12 2009-07-22 Boehringer Ingelheim Int VIRUS POLYMERASE INHIBITORS
ATE510846T1 (de) 2005-09-09 2011-06-15 Boehringer Ingelheim Int Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden
AU2006301966A1 (en) 2005-10-11 2007-04-19 Array Biopharma, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
AU2007253819B2 (en) 2006-05-23 2011-02-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
RU2009109355A (ru) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Ингибиторы вырусной полимеразы
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2104674T3 (pl) 2006-11-15 2013-12-31 Vertex Pharmaceuticals Canada Incorporated Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2009013827A (es) 2007-06-29 2010-03-01 Gilead Sciences Inc Compuestos antivirales.
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
JP5529036B2 (ja) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MX2011002828A (es) 2008-09-16 2011-04-05 Boehringer Ingelheim Int Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2750227A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8936781B2 (en) 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
JP5476859B2 (ja) * 2009-08-25 2014-04-23 住友化学株式会社 光学活性な１−アミノ−２−エテニルシクロプロパン−１−カルボン酸エチルまたはその酸付加塩の製造方法、およびその製造方法に用いられる中間体
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
JP2013515746A (ja) 2009-12-24 2013-05-09 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症の治療又は予防のための類似体
PE20121526A1 (es) 2010-01-27 2012-12-06 Pharma Ltd Ab Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011119870A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
JP2013529684A (ja) 2010-06-28 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
KR102163902B1 (ko) 2010-09-21 2020-10-12 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20130338392A1 (en) * 2011-03-10 2013-12-19 Sumitomo Chemical Company, Limited Method of producing optically active 1-amino-2-vinylcyclopropane carboxylic acid ester
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012269643A1 (en) 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
CN102807607B (zh) * 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
PE20142102A1 (es) 2011-12-06 2015-01-04 Univ Leland Stanford Junior Metodos y composiciones para tratar enfermedades virales
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
ES2613766T3 (es) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
WO2023149981A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268391A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
PT1003775E (pt) * 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.

Also Published As

Publication number Publication date
EP1105422A1 (en) 2001-06-13
SK2052001A3 (en) 2001-09-11
HUP0104548A2 (hu) 2002-04-29
CZ301405B6 (cs) 2010-02-17
NO20010604D0 (no) 2001-02-05
RS49819B (sr) 2008-08-07
KR20010087179A (ko) 2001-09-15
KR100629791B1 (ko) 2006-09-29
BR9912943A (pt) 2001-05-08
PL199419B1 (pl) 2008-09-30
ID27784A (id) 2001-04-26
EE200100080A (et) 2002-08-15
DK1105422T3 (da) 2006-06-19
NZ510395A (en) 2003-12-19
HUP0104548A3 (en) 2002-12-28
TR200100438T2 (tr) 2001-06-21
JP4435982B2 (ja) 2010-03-24
CZ2001515A3 (cs) 2001-07-11
YU9301A (sh) 2005-06-10
PL346051A1 (en) 2002-01-14
JP2002522557A (ja) 2002-07-23
WO2000009558A1 (en) 2000-02-24
ATE317854T1 (de) 2006-03-15
HK1039947B (zh) 2005-02-25
HK1039947A1 (en) 2002-05-17
ES2257066T3 (es) 2006-07-16
CA2336597A1 (en) 2000-02-24
CO5180537A1 (es) 2002-07-30
DE69929887D1 (en) 2006-04-20
EA004765B1 (ru) 2004-08-26
IL141011A (en) 2009-09-01
MY125014A (en) 2006-07-31
DE69929887T2 (de) 2006-08-24
BG64956B1 (bg) 2006-10-31
CN1315965A (zh) 2001-10-03
IL141011A0 (en) 2002-02-10
ZA200100972B (en) 2002-07-18
EP1105422B1 (en) 2006-02-15
BG105230A (en) 2001-10-31
HRP20010101A2 (en) 2002-02-28
SK286846B6 (sk) 2009-06-05
AR022061A1 (es) 2002-09-04
TW577895B (en) 2004-03-01
UA73480C2 (en) 2005-08-15
AU764655B2 (en) 2003-08-28
AU5273299A (en) 2000-03-06
EA200100229A1 (ru) 2001-10-22
CA2336597C (en) 2006-02-14
CN1166690C (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
DK1105422T3 (da) Hepatitis C-inhibitorpeptider
ATE430158T1 (de) Hepatitis c tripeptide inhibitoren
NO982097D0 (no) Peptider
NO982098L (no) Peptider
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
EE200000291A (et) 2-fenüülasendatud imidasotriasinoonid
NO995433D0 (no) Protease-inhibitorer
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
ID22380A (id) Turunan-turunan pirazol sebagai herbisida
NO995434L (no) Proteaseinhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE69903779D1 (de) Inhibitor- Schalter
DE69802791D1 (de) Ätzverfahren
NO20012283D0 (no) Koblede peptider
NO20013933D0 (no) Peptider
DK1012180T3 (da) Hepatitis C-inhibitorpeptidanaloger
SE9802536D0 (sv) Novel peptides
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
SE9700190D0 (sv) Rörklammer
KR970025254U (ko) 연습용 젓가락
BR9701096A (pt) Acertron iii

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application